Mylan launches new dosages of generic of Novartis hypertension drug in US

pharmafile | April 11, 2016 | News story | Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension 

Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor (metoprolol tartrate), making it the only manufacturer to offer the drug in five strengths.

The US Food and Drug Administration had already approved Mylan’s supplemental abbreviated new drug application (ANDA) for the additional dosages, which will now be available at 37.5mg and 75mg, as well as 25mg, 50mg and 100mg. Statistics from IMS Health suggest that the market for the previous three doses constituted approximately $68.9 million across all manufacturers for the 12 months to February 29 2016.

This high blood pressure generic treatment was just one of the 265 ANDAs that Mylan has filed and are currently pending approval from the FDA, which potentially represent $110.3 billion in annual brand sales.

Sean Murray

Related Content

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content